Microbiome and Volatile Organic Compounds in Patients With CDH (CDHVOCS)
Congenital Diaphragmatic Hernia
About this trial
This is an interventional basic science trial for Congenital Diaphragmatic Hernia focused on measuring congenital diaphragmatic hernia, volatile organic compounds, microbiome, pulmonary function, multiple breath washout
Eligibility Criteria
Inclusion Criteria:
- Age from 6-16 years
- Age 0-6 months at time of CDH-OP (except control group)
- reliable diagnosis of congenital diaphragmatic hernia (except control group)
- surgical occlusion with patch (except control group)
- surgical occlusion without patch (except control group)
- given approval
Exclusion Criteria:
- chronic pulmonary diseases
- Infection within 4 weeks before the test date
- unaccepted consent
Sites / Locations
- Department of Department of Pediatric and Adolescent Surgery, Medical University of Graz
Arms of the Study
Arm 1
Arm 2
Active Comparator
Other
CDH Group
Control Group
10 patients after surgical closure of CDH will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity). Thereafter patients will receive probiotic treatment with OmniBiotic6 (R) (Allergosan, Graz, Austria) 1 sachet daily for 3 months (probiotic treatment). Three months after discontinuing probiotic treatment VOC testing (VOC probiotics), fecal microbiome sampling (fecal microbiome probiotics) and deep induced sputum testing (pulmonary microbiome probiotics) will be repeated and compared to the results of the initial tests.
10 healthy controls (age and sex matched) will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity).